Condition
Lymphoma, Large Cell, Diffuse
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results75% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00322218Phase 3TerminatedPrimary
Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.
NCT00436280Phase 2CompletedPrimary
Chemotherapy for Participants With Lymphoma
NCT00689169Phase 2CompletedPrimary
Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma
NCT00532259Phase 2CompletedPrimary
CT-011 MAb in DLBCL Patients Following ASCT
Showing all 4 trials